演題詳細

ポスター / Poster

ポスター 13 (Poster 13) :MDS:臨床 2

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
太田 健 (Ken Ota):1
1:弘前大学大学院医学研究科 消化器血液内科学講座
 
前へ戻る

Peroxiredoxin 2 expression is elevated in the neutrophils of patients with myelodysplastic syndromes

演題番号 : PS-1-96

風間 啓至 (Hiroshi Kazama):1、寺村 正尚 (Masanao Teramura):1、栗原 佐知子 (Sachiko Kurihara):1、吉永 健太郎 (Kentaro Yoshinaga):1、加藤 智啓 (Tomohiro Kato):2、泉二 登志子 (Toshiko Motoji):1

1:Dept. Hematol. Tokyo Wemen's Medical Univ. Japan、2:Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine

 

Myelodysplastic syndromes (MDS) are heterogeneous clonal disorders characterized by cytopenias that arise due to ineffective hematopoiesis and morphological dysplasia that carry an increased risk of transformation to acute myeloid leukemia. The diagnosis of low-risk MDS can be difficult because of the paucity of molecular markers. Therefore, we investigated the proteome profile of circulating neutrophils purified from patients with refractory cytopenia with multilineage dysplasia (RCMD) to identify molecular markers of low-risk MDS. Using 2-dimensional difference gel electrophoresis (2D-DIGE) and protein identification by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry, we found that peroxiredonin-2 (Prx-2), a member of the peroxiredoxin family that regulates reactive oxygen species, was markedly higher in the neutrophils of MDS patients than in those of healthy donors. Increased Prx-2 expression in the neutrophils of MDS patients was confirmed by quantitative reverse transcriptase-polymerase chain reaction, immunoblotting, and immunocytochemistry. In addition, the number of neutrophils and platelets in MDS patients at the diagnosis was inversely correlated with the expression of Prx-2. This suggests that Prx-2 is a valuable biomarker for the diagnosis of low-risk MDS and is involved in the pathophysiology of low-risk MDS.

前へ戻る